Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E5555 in non-ST-segment elevation acute coronary syndrome
2006-000296-15Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atopaxar in acute coronary syndrome (ACS) and coronary arteriosclerosis (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Proportion of patients with CEC-adjudicated major bleeds and Safety and tolerability of E5555. Started Sep 2007; status: completed.
02
Drugs
atopaxar
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2006-000296-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000296-15.